World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
82
Citations
46918
World Ranking
15847
National Ranking
7976

Jordan Berlin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jordan Berlin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 557 publications — 66th percentile

66% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jordan Berlin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jordan Berlin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Jordan Berlin is affiliated with Vanderbilt University Medical Center in the United States. Their research primarily spans the fields of medicine and biochemistry, genetics, and molecular biology, with a significant focus on oncology and related subfields.

Their published work emphasizes topics including colorectal cancer treatments and studies, pancreatic and hepatic oncology research, and cancer genomics and diagnostics. Additional research interests cover lung cancer treatments and mutations, neuroendocrine tumor research advances, gastric cancer management and outcomes, as well as cancer immunotherapy and biomarkers.

Notable recent papers authored or co-authored by Jordan Berlin include:

  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials, 2020, published in The Lancet Oncology
  • Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial, 2021, published in Annals of Oncology
  • Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update, 2021, published in Journal of Clinical Oncology
  • The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022, published in ESMO Open
  • Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial, 2022, published in Journal of Clinical Oncology

The scientist frequently collaborates with peers such as Satya Das, Dana B. Cardin, Kristen K. Ciombor, David S. Hong, and Alexander Drilon, with whom they have co-authored numerous publications.

Their work is frequently published in venues including the Journal of Clinical Oncology, Annals of Oncology, Faculty Opinions - Post-Publication Peer Review of the Biomedical Literature, The Oncologist, and Cancer Research.

Best Publications

  • BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER

    Herbert Hurwitz;Louis Fehrenbacher;William Novotny;Thomas Cartwright

  • Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

    Jonathan Strosberg;G. El-Haddad;Edward Wolin;A. Hendifar

  • Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

    Alexander Drilon;Theodore W. Laetsch;Shivaani Kummar;Steven G. DuBois

  • The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

    Luis A. Diaz;Luis A. Diaz;Richard T. Williams;Jian Wu;Jian Wu;Isaac Kinde

  • Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

    Christine H. Chung;Beloo Mirakhur;Emily Chan;Quynh Thu Le

  • Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297

    Jordan D. Berlin;Paul Catalano;James P. Thomas;John W. Kugler

  • Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

    Herbert I. Hurwitz;Louis Fehrenbacher;John D. Hainsworth;William Heim

  • Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial

    Mace L. Rothenberg;Amit M. Oza;Robert H. Bigelow;Jordan D. Berlin

  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

    David S Hong;Steven G DuBois;Shivaani Kummar;Anna F Farago

  • Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

    Frank A. Scappaticci;Louis Fehrenbacher;Thomas Cartwright;John D. Hainsworth

  • Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Colon and Rectum

    Mary Kay Washington;Jordan Berlin;Philip Branton;Lawrence J. Burgart

  • Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

    Elizabeth Poplin;Yang Feng;Jordan Berlin;Mace L. Rothenberg

  • American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes

    Lee M. Ellis;David S. Bernstein;Emile E. Voest;Jordan D. Berlin

  • Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A. Mayer;Jennifer R. Diamond;Rebecca L. Moroose

  • Diagnosis and Treatment of Cholangiocarcinoma

    Christopher D. Anderson;C. Wright Pinson;Jordan Berlin;Ravi S. Chari

  • Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study

    Mark Kozloff;Marianne Ulcickas Yood;Jordan Berlin;Patrick J. Flynn

  • Neuroendocrine tumors, version 1.2015

    Matthew H. Kulke;Manisha H. Shah;Al B. Benson;Emily Bergsland

  • Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

    Alok A. Khorana;Pamela B. Mangu;Jordan Berlin;Anitra Engebretson

  • Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models.

    Michael L Schulte;Allie Fu;Ping Zhao;Jun Li

  • NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.

    Clark Oh;Benson Ab rd;Berlin Jd;Choti Ma

Frequent Co-Authors

Al B. Benson
Al B. Benson Northwestern University
Wells A. Messersmith
Wells A. Messersmith University of Colorado Boulder
Philip A. Philip
Philip A. Philip Wayne State University
David M. Goldenberg
David M. Goldenberg Immunomedics (United States)
David S. Hong
David S. Hong The University of Texas MD Anderson Cancer Center
Robert M. Sharkey
Robert M. Sharkey University of Fukui
Eileen M. O’Reilly
Eileen M. O’Reilly Memorial Sloan Kettering Cancer Center
Howard S. Hochster
Howard S. Hochster Yale University
Aditya Bardia
Aditya Bardia Harvard University
Robert J. Coffey
Robert J. Coffey Vanderbilt University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative routes in healthcare can help individuals find the right career fit and accelerate their professional journey. For example, those interested in advanced nursing roles may consider the easiest DNP programs, which offer flexible online options for experienced nurses to earn a Doctor of Nursing Practice and move into leadership positions.

If you’re seeking a faster entry into nursing, fastest LPN program pathways enable students to qualify as Licensed Practical Nurses in less time, often with online and hybrid learning for greater convenience. Similarly, the fastest PMHNP program options allow registered nurses to quickly specialize as Psychiatric Mental Health Nurse Practitioners, a field in high demand.

Apart from clinical roles, leadership and administrative positions are critical in healthcare. Pursuing an online Master of Health Administration is a practical path for those interested in managing medical facilities, policies, or systems. Each of these online programs opens new career doors and offers flexible solutions to meet educational and professional goals in medicine and healthcare.

Best Scientists Citing Jordan Berlin

Trending Scientists

Recently Published Articles